Abstract
Background In a recent phase III randomized control trial (FLAME), delivering a focal radiotherapy (RT) boost to tumors visible on MRI was shown to improve outcomes for prostate cancer patients without increasing toxicity. The aim of this study was to assess how widely this technique is being applied in current practice as well as physicians’ perceived barriers toward its implementation.
Methods An online survey assessing the use of intraprostatic focal boost was conducted in December 2022 and February 2023. The survey link was distributed to radiation oncologists worldwide via email list, group text platform, and social media.
Results The survey initially collected 205 responses from various countries over a two-week period in December 2022. The survey was then reopened for one week in February 2023 to allow for more participation, leading to a total of 263 responses. The highest-represented countries were the United States (42%), Mexico (13%), and the United Kingdom (8%). The majority of participants worked at an academic medical center (52%) and considered their practice to be at least partially genitourinary (GU)-subspecialized (74%).
57% of participants reported not routinely using intraprostatic focal boost. Even among complete subspecialists, a substantial proportion (39%) do not routinely use focal boost. Less than half of participants in both high-income and low-to-middle-income countries were shown to routinely use focal boost. The most commonly cited barriers were concerns about registration accuracy between MRI and CT (37%), concerns about risk of additional toxicity (35%), and challenges to accessing high-quality MRI (29%).
Conclusion Despite level 1 evidence from the FLAME trial, most radiation oncologists surveyed are not routinely offering focal RT boost. Adoption of this technique might be accelerated by increased access to high-quality MRI, better registration algorithms of MRI to CT simulation images, physician education on benefit-to-harm ratio, and training on contouring prostate lesions on MRI.
Competing Interest Statement
Dr. Tree declares research funding from Elekta, Varian Medical Systems, Inc., and Accuray as well as honoraria or travel assistance from Elekta, Accuray, and Janssen. Dr. Lui is a consultant for MIM software. Dr. Katz declares stock ownership with CVS Health, Dr. Reddy’s Laboratories, Healthcare Services, Quest Diagnostics, Teladoc Health, Pfizer, Moderna, and Bavarian Nordic. Dr. Murthy declares research funding from Varian Medical Systems, Inc. Dr. Stish declares research funding from Varian Medical Systems, Inc. Dr. Kishan declares research funding from ViewRay, Inc., Janssen, Inc., and Point Biopharmaceuticals, as well as honoraria and/or consulting fees from ViewRay, Inc., Janssen, Inc., Varian Medical Systems, Inc., and Boston Scientific. Dr. Seibert reports honoraria from Varian Medical Systems, Inc. and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board; he has received research grants from GE Healthcare through the University of California San Diego. These companies might potentially benefit from the research results. The terms of these arrangements have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.
Funding Statement
This work was supported, in part, by the National Institutes of Health (NIH/NIBIB K08EB026503, NIH UL1TR000100), the American Society for Radiation Oncology, and the Prostate Cancer Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of UC San Diego waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Methods and Results sections updated after reopening the survey in February 2023; new Figures 1 & 2 inserted; statistical analysis added to Table 1; Discussion section revised; Supplementary files updated.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
